Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).

Evan Y. Yu; Se Hoon Park; Jeffrey C. Goh; Sang Joon Shin; Niven Mehra; Raymond S. McDermott; Peter C. C. Fong; Richard Greil; Juan Pablo Sade; Yi-Hsiu Huang; Gero Kramer; Hiroyoshi Suzuki; Christian Heinrich Poehlein; Ping Qiu; E. J. Dettman; April Wang; Cai Chen; Razvan Cristescu; Matthew J. Marton; Emmanuel S. Antonarakis

Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).

Evan Y. Yu, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Niven Mehra, Raymond S. McDermott, Peter C. C. Fong, Richard Greil, Juan Pablo Sade, Yi-Hsiu Huang, Gero Kramer, Hiroyoshi Suzuki, Christian Heinrich Poehlein, Ping Qiu, E. J. Dettman, April Wang, Cai Chen, Razvan Cristescu, Matthew J. Marton, Emmanuel S. Antonarakis

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	16
Publication status	Published - 1 Jun 2024
Event	Special Clinical Science Symposia - Duration: 29 May 2024 → 29 May 2024

Cite this

Yu, E. Y., Park, S. H., Goh, J. C., Shin, S. J., Mehra, N., McDermott, R. S., Fong, P. C. C., Greil, R., Sade, J. P., Huang, Y.-H., Kramer, G., Suzuki, H., Poehlein, C. H., Qiu, P., Dettman, E. J., Wang, A., Chen, C., Cristescu, R., Marton, M. J., & Antonarakis, E. S. (2024). Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 42(16).

@article{c31b14da7fcc40559b5975cc3b04bf7c,

title = "Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).",

author = "Yu, {Evan Y.} and Park, {Se Hoon} and Goh, {Jeffrey C.} and Shin, {Sang Joon} and Niven Mehra and McDermott, {Raymond S.} and Fong, {Peter C. C.} and Richard Greil and Sade, {Juan Pablo} and Yi-Hsiu Huang and Gero Kramer and Hiroyoshi Suzuki and Poehlein, {Christian Heinrich} and Ping Qiu and Dettman, {E. J.} and April Wang and Cai Chen and Razvan Cristescu and Marton, {Matthew J.} and Antonarakis, {Emmanuel S.}",

year = "2024",

month = jun,

day = "1",

language = "English",

volume = "42",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "16",

note = "Special Clinical Science Symposia ; Conference date: 29-05-2024 Through 29-05-2024",

}

Yu, EY, Park, SH, Goh, JC, Shin, SJ, Mehra, N, McDermott, RS, Fong, PCC, Greil, R, Sade, JP, Huang, Y-H, Kramer, G, Suzuki, H, Poehlein, CH, Qiu, P, Dettman, EJ, Wang, A, Chen, C, Cristescu, R, Marton, MJ & Antonarakis, ES 2024, 'Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, vol. 42, no. 16.

Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC). / Yu, Evan Y.; Park, Se Hoon; Goh, Jeffrey C. et al.
In: Journal of Clinical Oncology, Vol. 42, No. 16, 01.06.2024.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Biomarkers associated with outcomes from KEYLYNK-010

T2 - Special Clinical Science Symposia

AU - Yu, Evan Y.

AU - Park, Se Hoon

AU - Goh, Jeffrey C.

AU - Shin, Sang Joon

AU - Mehra, Niven

AU - McDermott, Raymond S.

AU - Fong, Peter C. C.

AU - Greil, Richard

AU - Sade, Juan Pablo

AU - Huang, Yi-Hsiu

AU - Kramer, Gero

AU - Suzuki, Hiroyoshi

AU - Poehlein, Christian Heinrich

AU - Qiu, Ping

AU - Dettman, E. J.

AU - Wang, April

AU - Chen, Cai

AU - Cristescu, Razvan

AU - Marton, Matthew J.

AU - Antonarakis, Emmanuel S.

PY - 2024/6/1

Y1 - 2024/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001275557401309&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Abstract (Journal)

SN - 0732-183X

VL - 42

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

Y2 - 29 May 2024 through 29 May 2024

ER -

Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).

Other files and links

Cite this